Philippe Huot-Marchand

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · New England Journal of Medicine · 2021 · 721 citations · Full text

Medicine, Internal Medicine, Pharmacology +15

Evaluation of a Streamlined Oncologist-Led <i>BRCA</i> Mutation Testing and Counseling Model for Patients With Ovarian Cancer

Nicoletta Colombo, Gloria S. Huang, Giovanni Scambia et al. · Journal of Clinical Oncology · 2018 · 97 citations · Full text

Medicine, Genetics, Oncology +13

A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study

Francque Sven M., Bedossa Pierre, Abdelmalek Manal F. et al. · Contemporary Clinical Trials · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD

Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva et al. · Journal of Hepatology · 2025 · 70 citations · Full text

Medicine, Endocrinology, Pharmacology +14

The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis

Michael Cooreman, Javed Butler, Robert P. Giugliano et al. · Nature Communications · 2024 · 61 citations · Full text

Medicine, Endocrinology, Pharmacology +17